Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials.
- 2022-08-01
- Review
- Interactive journal of medical research 11(2)
- Aneesh Basheer
- Ayush Agarwal
- Biswamohan Mishra
- Anu Gupta
- Madakasira Vasantha Padma Srivastava
- Richard Kirubakaran
- Venugopalan Vishnu
- PubMed: 35612544
- DOI: 10.2196/38542
- Low evidence
- Clinical
While all studies reported a statistically significant difference between B. monnieri and the comparator in at least one outcome, we rated the overall quality of evidence for the Alzheimer's Disease Assessment Scale-Cognitive Subscale ... to be very low due to downgrading by 2 levels for high risk of bias and 1 more level for impreciseness due to small sample sizes and wide CIs.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 125 mg to 500 mg twice daily